The mixed data from the Phase III COAST 2 trial follows an underwhelming data drop from COAST 1 in September that Leerink ...

The FDA’s rare pediatric disease priority review voucher program missed reauthorization at the last minute in 2024; advocates ...

Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as ...

I don’t like established science,” ACIP chairperson Kirk Milhoan said in an interview on the Why Should I Trust You? podcast.

The U.S. regulator shared the roadmap for implementing the program, first proposed in August 2025, and teased changes made in response to industry feedback.

The company also stands to gain from recent regulatory FDA guidance aimed at streamlining the development of non-opioid ...

Pfizer CEO Albert Bourla said that the main thing getting in the way of changing vaccine discussions in the U.S. is the ...

In this episode of Denatured, BioSpace editorial team members, Senior Editor, Annalee Armstrong, and News Editor, Dan ...

Fueled by advances in biomarkers, brain mapping, and AI, investment in neuro and CNS innovation shows no signs of slowing, ...

Competition for biotech and pharma employment picked up year over year and remains strong, according to BioSpace data. A survey late last year showed that 64% of employed/contract and 96% of ...

Looking for a research and development job? Check out the BioSpace list of 12 companies hiring life sciences professionals like you.

Reporting Q4 and full year earnings on Wednesday, J&J executives hailed growth across the healthcare giant’s portfolio while ...